Gregory Norden Biography and Net Worth

Director of Royalty Pharma

Greg Norden is the former Chief Financial Officer of Wyeth. In addition, Greg is the Managing Director of G9 Capital Group, LLC, which invests in early-stage ventures and provides corporate advisory services. Greg also serves on the Boards of Zoetis, the leading animal health company and Praxis, a clinical-stage biopharmaceutical company. Greg is a former director of Human Genome Sciences, Univision and Welch Allyn. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co, working primarily with multinational companies in the life sciences, consumer goods and financial services industries. Greg has a BS in Management and Economics from State University of New York at Plattsburgh and an MS in Accounting from LIU Post.

What is Gregory Norden's net worth?: The estimated net worth of Gregory Norden is at least $10.05 million as of May 14th, 2026. Norden owns 191,803 shares of Royalty Pharma stock worth more than $10,052,395 as of May 20th. This net worth estimate does not reflect any other assets that Norden may own. Learn More about Gregory Norden's net worth.
How do I contact Gregory Norden?: The corporate mailing address for Norden and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Gregory Norden's contact information.
Has Gregory Norden been buying or selling shares of Royalty Pharma?: During the last quarter, Gregory Norden has sold $161,385.00 in shares of Royalty Pharma stock. Most recently, Gregory Norden sold 3,045 shares of the business's stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $53.00, for a transaction totalling $161,385.00. Following the completion of the sale, the director now directly owns 191,803 shares of the company's stock, valued at $10,165,559. Learn More on Gregory Norden's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (Founder & Chief Executive Officer and Chairman), George Lloyd (EVP), Gregory Norden (Director), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, insiders at the biopharmaceutical company sold shares 32 times. They sold a total of 1,465,109 shares worth more than $59,527,724.26. The most recent insider tranaction occured on May, 14th when EVP Marshall Urist sold 13,684 shares worth more than $726,073.04. Insiders at Royalty Pharma own 18.8% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 5/14/2026.

Gregory Norden Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/14/2026	Sell	3,045	$53.00	$161,385.00	191,803

Gregory Norden Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $52.41

$51.81

$52.62

50 Day Range

MA: $48.58

$45.36

$53.40

2 Week Range

Now: $52.41

$32.15

$53.47

Volume

3,808,373 shs

Average Volume

3,659,603 shs

Market Capitalization

$30.18 billion

P/E Ratio

35.65

Dividend Yield

1.81%

Beta

0.4